2Seventy Bio Inc
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. 2seventy bio, Inc. was inco… Read more
2Seventy Bio Inc (TSVT) - Net Assets
Latest net assets as of March 2025: $213.96 Million USD
Based on the latest financial reports, 2Seventy Bio Inc (TSVT) has net assets worth $213.96 Million USD as of March 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($480.00 Million) and total liabilities ($266.04 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $213.96 Million |
| % of Total Assets | 44.57% |
| Annual Growth Rate | 36.97% |
| 5-Year Change | 182.47% |
| 10-Year Change | N/A |
| Growth Volatility | 154.41 |
2Seventy Bio Inc - Net Assets Trend (2019–2024)
This chart illustrates how 2Seventy Bio Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for 2Seventy Bio Inc (2019–2024)
The table below shows the annual net assets of 2Seventy Bio Inc from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $210.81 Million | -17.43% |
| 2023-12-31 | $255.30 Million | -17.77% |
| 2022-12-31 | $310.47 Million | -13.72% |
| 2021-12-31 | $359.82 Million | +382.15% |
| 2020-12-31 | $74.63 Million | +70.81% |
| 2019-12-31 | $43.69 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to 2Seventy Bio Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 56846400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $5.00K | 0.00% |
| Other Comprehensive Income | $89.00K | 0.04% |
| Other Components | $779.18 Million | 369.62% |
| Total Equity | $210.81 Million | 100.00% |
2Seventy Bio Inc Competitors by Market Cap
The table below lists competitors of 2Seventy Bio Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
CK Life Sciences Int'l. (Holdings) Inc
F:LSI
|
$213.50 Million |
|
Shenzhen Wongtee International Enterprise Co Ltd
SHE:000056
|
$213.53 Million |
|
Lintes Technology Co Ltd
TW:6715
|
$213.62 Million |
|
Wuxi Xinhongye Wire & Cable Co. Ltd. A
SHE:301310
|
$213.72 Million |
|
Beijing Changjiu Logistics Ltd
SHG:603569
|
$213.49 Million |
|
Movida Participações S.A
SA:MOVI3
|
$213.48 Million |
|
Nanjing Panda Electronics Company Limited
F:NNJ
|
$213.43 Million |
|
Penns Woods Bancorp Inc
NASDAQ:PWOD
|
$213.37 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in 2Seventy Bio Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 255,300,000 to 210,806,000, a change of -44,494,000 (-17.4%).
- Net loss of 57,247,000 reduced equity.
- Other comprehensive income increased equity by 293,000.
- Other factors increased equity by 12,460,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-57.25 Million | -27.16% |
| Other Comprehensive Income | $293.00K | +0.14% |
| Other Changes | $12.46 Million | +5.91% |
| Total Change | $- | -17.43% |
Book Value vs Market Value Analysis
This analysis compares 2Seventy Bio Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.24x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 2.66x to 1.24x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $1.88 | $5.00 | x |
| 2020-12-31 | $3.20 | $5.00 | x |
| 2021-12-31 | $15.26 | $5.00 | x |
| 2022-12-31 | $8.71 | $5.00 | x |
| 2023-12-31 | $5.18 | $5.00 | x |
| 2024-12-31 | $4.04 | $5.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently 2Seventy Bio Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -27.16%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -151.20%
- • Asset Turnover: 0.08x
- • Equity Multiplier: 2.27x
- Recent ROE (-27.16%) is above the historical average (-200.11%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -740.05% | -729.96% | 0.14x | 7.21x | $-327.71 Million |
| 2020 | -185.14% | -55.69% | 0.79x | 4.19x | $-145.63 Million |
| 2021 | -81.21% | -535.95% | 0.07x | 2.11x | $-328.20 Million |
| 2022 | -81.86% | -277.77% | 0.14x | 2.12x | $-285.19 Million |
| 2023 | -85.22% | -216.73% | 0.18x | 2.21x | $-243.10 Million |
| 2024 | -27.16% | -151.20% | 0.08x | 2.27x | $-78.33 Million |
Industry Comparison
This section compares 2Seventy Bio Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| 2Seventy Bio Inc (TSVT) | $213.96 Million | -740.05% | 1.24x | $213.50 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |